Delving into the Latest Updates on Succimer with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

DIM-SA, DMS, DMS-A

+ [8]

Target-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Mercury PoisoningLead Poisoning

Inactive Indication-

Originator Organization

Recordati SpA

Active Organization

Recordati Rare Diseases, Inc.

Shanghai Pharmaceuticals Holding Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (30 Jan 1991),

Lead Poisoning

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC4H6O4S2

InChIKeyACTRVOBWPAIOHC-XIXRPRMCSA-N

CAS Registry304-55-2

Based on the genotype characteristics and genotype-phenotype-treatment prognosis data of Chinese WD patients, this study intends to further optimize the treatment regimen of Chinese WD patients and formulate individualized treatment regimens for each genotype, so as to further improve the prognosis of patients.

Start Date15 Mar 2019

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

NCT03630991 / RecruitingPhase 1IIT

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Therapy

This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy.

Start Date11 Oct 2018

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

IRCT20180131038581N1 / SuspendedPhase 3IIT

Comparison of treatment response to Calcium EDTA and succimer in patients being intoxicated with lead by taking oral opium

Start Date07 Oct 2018

Sponsor / Collaborator-

100 Clinical Results associated with Succimer

Login to view more data

100 Translational Medicine associated with Succimer

Login to view more data

100 Patents (Medical) associated with Succimer

Login to view more data

2,345

Literatures (Medical) associated with Succimer

01 Jan 2025·Marine Environmental Research

DMS behaviors in pen culture of Sinonovacula constricta in Longhai, China

Article

Author: Zhang, Miming ; Wang, Nuoxuan ; Tian, Rong ; Yan, Shibo ; Yan, Jinpei ; Lv, Shengbin ; Zhang, Chao ; Wang, Bingkun ; Wang, Shanshan

Dimethyl sulfide (DMS) released by the ocean has received widespread attention due to its role in aerosol formation and impact on global climate change. Research on DMS mainly focuses on coastal and open ocean environments, with limited studies addressing the influence of aquaculture activities on the production and release of marine DMS. Thus, we investigated whether fertilization for algae cultivation and the feeding process in pen culture of Sinonovacula constricta significantly contribute to DMS release. We found notable diurnal variations in DMS concentrations during and after the culture period in the ponds. During the post-culture period, both the concentration and flux of DMS in the ponds were higher than those during the culture period. The average flux of DMS during the culture and post-culture period were only 0.1 ± 0.1 μmol/(m²·d) and 0.4 ± 0.3 μmol/(m²·d), respectively, indicating that aquaculture activities of Sinonovacula constricta may not produce or release substantial DMS when compared with those from the coastal aeras and open oceans.

01 Dec 2024·International Journal of Biological Macromolecules

Temperature-sensitive injectable chitosan-based hydrogel for endoscopic submucosal dissection

Article

Author: Zhang, Zhenguo ; Jiang, Zhen ; Liu, Wanshun ; Liu, Shourui ; Ju, Ruibao ; Cui, Jingzhao ; Wang, Shuo ; Han, Baoqin

Endoscopic submucosal dissection (ESD) is an effective treatment for polyps and early gastrointestinal cancers, but requires a high level of operator skill. Injecting submucosal materials (SIM) helps create a fluid cushion between the mucosal and muscular layers, making the procedure easier and reducing associated risks. However, SIMs commonly used in current clinical practice tend to spread quickly and fail to provide long-lasting submucosal fluid cushions (SFC). Thus, there is a critical need for a material that is easy to inject while also maintaining a durable barrier. We prepared succinylated hydroxybutyl chitosan (HBC-SA) by adding succinic anhydride (SA) to hydroxybutyl chitosan (HBC). The hydrogel had excellent temperature-sensitive properties and was able to be injected via an endoscopic injection needle even after gel formation. In vitro and in vivo studies showed that it has satisfactory biocompatibility. Functional experiments showed that the submucosal lifting properties of this hydrogel were significantly better than that of normal saline (NS) and sodium hyaluronate (SH), two commonly used clinical materials. In addition, the hydrogel possessed excellent hemostatic properties. Based on these results, HBC-SA is a promising candidate for submucosal injection during ESD.

01 Dec 2024·Colloids and Surfaces B: Biointerfaces

Efficient delivery of curcumin by functional solid lipid nanoparticles with promoting endosomal escape and liver targeting properties

Article

Author: Liang, Ying ; Liang, Ju ; Zhang, Mengyi ; Wu, Wenlan ; Li, Xuening

In the realm of intracellular drug delivery, overcoming the barrier of endosomal entrapment stands as a critical factor influencing the effectiveness of nanodrug delivery systems. This study focuses on the synthesis of an acid-sensitive fatty acid derivative called imidazole-stearic acid (IM-SA). Leveraging the proton sponge effect attributed to imidazole groups, IM-SA was anticipated to play a pivotal role in facilitating endosomal escape. Integrated into the lipid core of solid lipid nanoparticles (SLNs), IM-SA was paired with hyaluronic acid (HA) coating on the surface of SLNs loading with curcumin (CUR). The presence of IM-SA and HA endowed HA-IM-SLNs@CUR with dual functionalities, enabling the promotion of endosomal escape, and specifical targeting of liver cancer. HA-IM-SLNs@CUR exhibited a particle size of ∼228 nm, with impressive encapsulation efficiencies (EE) of 87.5 % ± 2.3 % for CUR. Drugs exhibit significant pH sensitive release behavior. Cellular experiments showed that HA-IM-SLN@CUR exhibits enhanced drug delivery capability. The incorporation of IM-SA significantly improved the endosomal escape of HA-IM-SLN@CUR, facilitating accelerated intracellular drug release and increasing intracellular drug concentration, exhibiting excellent growth inhibitory effects on HepG2 cells. Animal experiments revealed a 3.4-fold increase in CUR uptake at the tumor site with HA-IM-SLNs@CUR over the free CUR, demonstrating remarkable tumor homing potential with the tumor growth inhibition rate of 97.2 %. These findings indicated the significant promise of HA-IM-SLNs@CUR in the realm of cancer drug delivery.

100 Deals associated with Succimer

Login to view more data